GLP-1 Peptide Synthesis CDMO Market Research Report with Forecast 2025 to 2034

Global GLP-1 Peptide Synthesis CDMO Market Size is predicted to grow at a 12.7 % CAGR during the forecast period for 2025 to 2034.

GLP-1 Peptide Synthesis CDMO Market, Share & Trends Analysis Report, By Synthesis Technology (Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), Group-Assisted Purification Peptide Synthesis (GAP-PS), Hybrid Technology, Recombinant DNA Technology), By Service Type (Analytical and Process Development, Large-Scale Production, Custom Peptide Synthesis, Peptide Modification, Purification Technology, Formulation Development, Regulatory Support, Packaging and Labeling, Pre-Formulation and Registration Batches), By Scale of Operation, By End-User, By Region, and Segment Forecasts, 2025 to 2034.

GLP-1 peptide synthesis CDMOs specialize in GLP-1 peptide synthesis, offering services from research-grade to GMP-compliant production for pharmaceutical applications.

GLP-1 (Glucagon-Like Peptide-1) is a peptide hormone synthesized from the proglucagon gene in intestinal L-cells and certain neurons. It plays a crucial role in regulating blood sugar levels by stimulating insulin release and inhibiting glucagon secretion.

Advanced techniques such as solid-phase peptide synthesis (SPPS), solution-phase synthesis, or hybrid methods are used to produce GLP-1 peptides. These peptides can be manufactured at various scales, ranging from small research batches to large-scale commercial production, ensuring their availability for both scientific and therapeutic applications. Drug companies often prefer to outsource GLP-1 peptide synthesis to CDMOs due to the complexity and scalability challenges associated with this process as CDMOs offer specialized expertise, advanced infrastructure, and cost-effective solutions for both research and large-scale production of GLP-1 peptides.

Factors such as surging market demand for the global GLP-1 receptor agonists, therapeutic expansion of GLP-1 Beyond diabetes in obesity, cardiovascular diseases, and neurodegenerative disorders treatment, sophisticated synthesis requirements for GLP-1 peptides (e.g., solid-phase peptide synthesis or hybrid approaches), high-purity standards, and impurity control, shortages of high-quality raw materials and the need for cost-effective, sustainable manufacturing and stringent FDA and EMA requirements for GMP-grade peptides fuel the need for scalable, high-quality peptide production and drug manufacturing companies to outsource manufacturing to the GLP-1 peptide synthesis CDMOs.

The growing global prevalence of type 2 diabetes and obesity has significantly increased demand for GLP-1 receptor agonists such as semaglutide, liraglutide, and tirzepatide, which are known for their ability to manage blood glucose levels, support weight loss, and improve cardiovascular outcomes. This surge in demand is driving the need for large-scale peptide production, making CDMOs essential partners in this process. As peptides gain popularity for their high selectivity, potency, and favorable safety profiles, GLP-1 analogues have emerged as a key segment within the peptide therapeutics market, encouraging pharmaceutical companies to outsource their production to specialized CDMOs increasingly.

Competitive Landscape

Some of the Major Key Players in the GLP-1 Peptide Synthesis CDMO Market are

• Bachem Holding AG
• CordenPharma
• PolyPeptide Group
• AmbioPharm
• CPC Scientific
• CSBio
• Creative Peptides
• Lonza
• Aurisco Pharmaceutical
• Hybio Pharmaceuticals
• Chinese Peptide Company
• Neuland Laboratories
• Divis Laboratories
• Supriya Lifescience
• Allsino Pharmaceutical Co. Ltd

Market Segmentation

The GLP-1 peptide synthesis CDMO market is segmented based on synthesis technology, service type, scale of operation, and end-user. Based on synthesis technology, the market is segmented into solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), group-assisted purification peptide synthesis (GAP-PS), hybrid technology, and recombinant DNA technology.

Based on the type of service, the market is divided into analytical and process development, large-scale production, custom peptide synthesis, peptide modification, purification technology, formulation development, regulatory support, packaging and labeling, pre-formulation, and registration batches. Based on the scale of operation, the market is divided into clinical-scale manufacturing, commercial-scale manufacturing, and pilot-scale manufacturing. Based on the end-user, the market is divided into pharmaceutical companies, biotechnology companies, and research institutions.

The Solid-Phase Peptide Synthesis (SPPS) Segment is Expected to Have the Highest Growth Rate During the Forecast Period

The solid-phase peptide synthesis (SPPS) segment is expected to have the highest growth rate during the forecast period. GLP-1 analogues, such as semaglutide and other long-chain, structurally complex peptides, are best synthesised via solid-phase peptide synthesis (SPPS).  Compared to solution-phase techniques, it permits the gradual addition of amino acids, providing for more control and oversight.  To improve the stability, bioactivity, and pharmacokinetics of GLP-1 analogues, SPPS also supports the addition of non-natural amino acids, PEGylation, lipidation, and other chemical modifications.  Due to these qualities, SPPS is a crucial platform for the creation and manufacture of future-generation GLP-1 receptor agonists.

The Large-scale Production Segment to Dominate the Market

The large-scale production segment is expected to dominate the market. There is a demand for kilogram-scale, GMP-compliant peptide manufacturing, as many GLP-1 analogues have progressed from clinical development to full commercialization. Large-scale CDMOs are crucial for providing reliable, superior, and legally compliant manufacturing at industrial scales. The cost-per-gram of peptide active pharmaceutical ingredients (APIs) is significantly decreased by economies of scale made possible by large-scale manufacture. Pharmaceutical businesses seeking dependable and efficient manufacturing partners find CDMOs with automated solid-phase peptide synthesis (SPPS) systems and optimized batch processes to be highly appealing, as they can offer competitive pricing and expedited turnaround times.

North America Has the Largest Market Share During the Forecast Period.

North America, particularly the US, is one of the largest markets for GLP-1 receptor agonists such as Ozempic, Wegovy, and Mounjaro. The demand for GLP-1 analogue manufacture is greatly influenced by the fact that the US leads the world in pharmaceutical research and development, particularly in the fields of diabetes and obesity treatments. The region's CDMOs are favored partners for the clinical and commercial-scale manufacturing of GLP-1 peptides due to their sophisticated infrastructure and strict adherence to FDA standards. The market in North America is expected to increase due to its sophisticated manufacturing capabilities, robust pharmaceutical demand, and concentration of top-tier CDMOs that can support large-scale clinical and commercial peptide production.

Recent Developments:

• In Mar 2025, CordenPharma launched a greenfield peptide manufacturing plant in Basel, Switzerland, into operation. The company's 541 million investment is a component of a three-year peptide drive worth $1.08 billion.  The strategy, which was unveiled in July 2024, intends to increase the production of glucagon-like peptide-1 (GLP-1) peptide in both the US and Europe.  For both GLP-1 and non-GLP-1 peptide projects, the factory will include many peptide production manufacturing lines with solid phase peptide synthesis (SPPS) reactors larger than 5,000 L.  The facility will comply with biologics license applications (BLAs) thanks to its cutting-edge automation and creative peptide manufacturing technology.
• In Mar 2024, Aurisco Pharmaceutical invested in cGMP peptide manufacturing capacity at its USFDA-inspected location in Yangzhou, China. The new advanced production and purification workshops offer a multi-metric ton capability to create Aurisco's generic GLP-1 peptides in addition to its existing fermentation and synthetic capabilities.  With the confirmation of recombinant semaglutide on a commercial scale, the state-of-the-art facilities are scheduled to open in mid-2024.
• In September 2024, SK pharmteco invested US$260 million to establish a five-story, 135,800-square-foot facility in Sejong, South Korea, to enhance the its peptide and small-molecule API manufacturing capabilities.

GLP-1 Peptide Synthesis CDMO Market Report Scope